Evenity (Romosozumab) Missed-Dose Protocol: What to Do and Why Timing Matters

How Romosozumab Works: The Sclerostin Connection

Romosozumab is the only FDA-approved osteoporosis drug that simultaneously builds new bone and slows bone breakdown. It achieves this by binding sclerostin, a glycoprotein secreted by osteocytes that normally suppresses the Wnt signaling pathway responsible for osteoblast differentiation and activity 1.

When sclerostin is neutralized, Wnt signaling ramps up. Osteoblasts proliferate, deposit new matrix, and mineralize it. At the same time, romosozumab lowers RANKL expression and raises OPG expression, which together reduce osteoclast-mediated resorption 2. This dual mechanism is what separates romosozumab from every other agent in the osteoporosis formulary. Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic but also stimulate resorption markers over time. Bisphosphonates and denosumab are purely antiresorptive. Romosozumab does both, but its anabolic window is finite.

Bone formation markers tell the story. Serum P1NP (procollagen type I N-terminal propeptide) surges by roughly 140% from baseline within the first month of treatment, then progressively declines, returning near baseline by month 9 3. The resorption marker CTX drops early and stays suppressed throughout the 12-month course. This asymmetry means the strongest bone-building happens in the first few months, and each missed or delayed dose during that window carries an outsized cost.

The Official Missed-Dose Guidance

The FDA-approved prescribing information for Evenity states: if a dose is missed, administer it as soon as possible, then schedule the next dose no sooner than one month from the date the missed dose was given 4. The total treatment course should not exceed 12 doses.

That single sentence is all the label provides. It does not distinguish between a dose delayed by a few days and one delayed by several weeks. It does not specify whether the 12-dose limit is absolute or whether additional doses might be warranted in cases of extended interruption. Clinicians are left to extrapolate from pharmacokinetic data and trial design.

In the FRAME and ARCH registration trials, protocol deviations for missed doses were managed by administering the injection at the next scheduled visit, effectively skipping that month 3 5. Patients who missed doses remained in the intent-to-treat population, but subgroup efficacy data for dose-delayed patients were not separately reported in the primary publications.

Why Timing Matters More for Romosozumab Than Other Osteoporosis Drugs

A delayed bisphosphonate dose is a minor inconvenience. Alendronate has a skeletal half-life measured in years; missing one weekly tablet barely registers on a DXA scan. Romosozumab is fundamentally different. Three features explain why.

The anabolic window is self-limiting. Sclerostin levels begin to recover between doses, and with each successive dose the P1NP response flattens. By month 6, the formation marker boost is roughly one-third of what it was at month 1, based on phase II dose-response data published in the Journal of Bone and Mineral Research 6. Missing a dose early in the course means losing time at the top of the response curve, something that cannot be recaptured by adding a dose at the end.

The 12-dose ceiling is firm. FDA labeling does not authorize treatment beyond 12 months. Extension studies have not demonstrated continued anabolic benefit past this point. Sclerostin antibody tachyphylaxis appears biologically intrinsic to the Wnt pathway feedback loop, not simply a dosing issue 7.

Post-treatment bone loss is rapid without antiresorptive sequencing. BMD gains achieved during romosozumab treatment erode within 12 months if no antiresorptive agent follows. The ARCH trial protocol transitioned all patients to alendronate after the 12-month romosozumab phase, and the fracture reduction advantage over alendronate-only persisted through month 24 precisely because of this sequencing 3. Delays during the romosozumab phase push back the start of antiresorptive coverage, leaving a longer vulnerable interval.

Practical Decision Framework for Clinicians

No randomized trial has compared outcomes across different missed-dose strategies. The following framework is derived from pharmacokinetic modeling, bone-marker kinetics, and expert consensus from the American Association of Clinical Endocrinology (AACE) 2020 guidelines for postmenopausal osteoporosis management 8.

Delay of 1 to 7 days. Administer the injection immediately. Resume the normal monthly schedule from this new date. The pharmacokinetic half-life of romosozumab is approximately 12.8 days; a delay under one week keeps trough levels well above the threshold for sclerostin suppression.

Delay of 1 to 4 weeks. Give the missed dose as soon as possible. Reschedule all remaining doses monthly from the new administration date. Do not attempt to "double up" or shorten the interval to the next planned dose. Count this as one of the 12 lifetime doses.

Delay exceeding 4 weeks. Administer the dose immediately. Be aware that sclerostin levels have likely rebounded fully, and the subsequent dose will produce a response curve more similar to an early-treatment dose, but the total anabolic capacity of the 12-month course has been partially consumed by the gap. If the gap exceeds 8 weeks, consider rechecking P1NP at the next visit to confirm a bone-formation response. Some clinicians in this scenario discuss with the patient whether the lost month should be "replaced" by adding a 13th month, though this is off-label and not supported by trial data.

Multiple consecutive missed doses (2 or more months). Reassess the treatment plan entirely. Recheck the DXA T-score and FRAX probability. If the patient has received fewer than 6 of the planned 12 doses and the gap is long enough that the anabolic window has substantially closed, an alternative strategy (e.g., switching to teriparatide or abaloparatide, or proceeding directly to antiresorptive therapy) may be more appropriate than resuming romosozumab mid-course.

Bone Density Gains at Stake

The FRAME trial (N=7,180) randomized postmenopausal women to romosozumab 210 mg monthly or placebo for 12 months, followed by denosumab in both arms. At month 12, romosozumab produced a 13.3% increase in lumbar spine BMD and a 6.9% increase in total hip BMD versus baseline 5. These are the largest BMD gains reported for any osteoporosis agent in a single year.

The ARCH trial (N=4,093) compared romosozumab to alendronate, both followed by alendronate. Romosozumab reduced the risk of new vertebral fracture by 48% compared with alendronate through 24 months (incidence 6.2% vs. 11.9%, P<0.001) 3.

Every missed dose represents a smaller fraction of that 13.3% lumbar gain realized. Phase II data showed the BMD response at the lumbar spine was roughly linear across the first 6 months and then began to plateau 6. Missing a dose in months 1 through 4 carries more absolute BMD cost than missing one in months 9 through 12, when the anabolic contribution per dose has already diminished.

"The therapeutic window for romosozumab is uniquely compressed compared to other anabolic agents," noted Dr. Felicia Cosman, Professor of Clinical Medicine at Columbia University, in a 2019 review of sequential osteoporosis therapy. "Clinicians should treat the 12-month course as non-negotiable and counsel patients that each monthly injection counts" 9.

Cardiovascular Safety and the Urgency to Stay on Schedule

Romosozumab carries a boxed warning for potential cardiovascular risk. In ARCH, the romosozumab group experienced more adjudicated major adverse cardiovascular events (MACE) than the alendronate group during the first 12 months (2.5% vs. 1.9%), though the absolute difference was small and the FRAME trial (romosozumab vs. placebo) did not confirm an excess 3 5. The FDA contraindicated romosozumab in patients who have had a myocardial infarction or stroke within the preceding year 4.

This cardiovascular signal creates an additional reason not to extend the treatment beyond 12 calendar months. If missed doses push the course past month 12, clinicians must weigh the incremental fracture-reduction benefit of completing all 12 doses against the incremental cardiovascular exposure. There is no published guidance on this exact trade-off.

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis recommended that "patients receiving romosozumab should be monitored for cardiovascular events and the drug should be avoided in patients at high cardiovascular risk" 10. That caution applies with particular force when treatment duration is being extended to accommodate missed doses.

How to Sequence Therapy After Romosozumab

The gains from romosozumab disappear without follow-on antiresorptive therapy. A 2020 analysis of FRAME extension data showed that patients transitioned to denosumab after romosozumab maintained and extended their BMD gains through 36 months, while those who received placebo followed by denosumab never caught up to the romosozumab-first group 11.

If a patient's romosozumab course is interrupted and fewer than 12 doses are completed, the transition to antiresorptive therapy becomes even more time-sensitive. Two options predominate:

Oral bisphosphonate (alendronate 70 mg weekly or risedronate 150 mg monthly). Start within 30 days of the last romosozumab injection. The ARCH trial used this exact sequence and confirmed sustained fracture protection at 24 months 3.

Denosumab 60 mg every 6 months. Offers greater BMD consolidation than bisphosphonates. The FRAME trial confirmed that denosumab following romosozumab produced the highest BMD values at every skeletal site measured at 24 months 5. The trade-off: denosumab itself requires strict adherence, as discontinuation triggers rebound bone loss and vertebral fracture risk.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, emphasized this in a 2020 review: "Romosozumab should always be viewed as the first act of a two-part treatment sequence. The second act, antiresorptive consolidation, is what locks in the skeletal benefit" 12.

Monitoring Bone Turnover Markers During Treatment

Bone turnover markers are not required by the FDA label, but they offer the only real-time feedback on whether romosozumab is working. DXA scans are typically performed at baseline and at 12 months; they cannot detect a mid-course gap.

P1NP (bone formation marker). Expect a peak at month 1 (median increase of roughly 100 to 150% above baseline), with progressive decline thereafter. If a patient has missed two or more doses and P1NP is checked at the next visit, a value near baseline suggests the anabolic window has closed and remaining doses may yield minimal formation stimulus 6.

CTX (bone resorption marker). Remains suppressed throughout the 12-month course regardless of the P1NP trajectory. A CTX that has rebounded to baseline mid-course signals prolonged drug absence and warrants clinical reassessment.

Neither marker is validated as a treatment-adjustment tool in prospective trials. Their use remains expert-opinion-level evidence. The International Osteoporosis Foundation (IOF) and the European Calcified Tissue Society (ECTS) jointly recommended P1NP and CTX as reference markers for monitoring osteoporosis therapy response in a 2019 position paper 13.

Patient Counseling: Preventing Missed Doses

Romosozumab is administered in a healthcare setting (two subcutaneous injections of 105 mg each, for a total of 210 mg per visit). Unlike daily oral medications, adherence depends on keeping a monthly appointment. Barriers include transportation, scheduling conflicts, cost, and insurance prior authorization delays.

Practical measures that reduce missed-dose risk:

• Schedule all 12 monthly appointments at treatment initiation.
• Set electronic calendar reminders 7 days and 1 day before each visit.
• Coordinate with the pharmacy or specialty distributor to confirm drug availability before each visit. Evenity requires cold-chain storage and is dispensed through specialty channels; supply-side delays are not uncommon.
• If the patient is traveling, arrange for administration at a satellite clinic or infusion center. Romosozumab does not require infusion, only subcutaneous injection, so any provider with access to the drug can administer it.
• Address cost barriers early. The wholesale acquisition cost of Evenity is approximately $1,825 per monthly dose (as of 2025), and most commercial plans require prior authorization. Amgen's patient assistance program covers eligible uninsured and underinsured patients 4.

The 12-month course of romosozumab at the recommended dose of 210 mg subcutaneously once monthly, with each missed dose given as soon as possible and subsequent doses rescheduled monthly from the new date, produces the fracture-reduction benefit demonstrated in ARCH: 48% fewer new vertebral fractures compared with alendronate over 24 months (P<0.001) 3.